IDEAYA Biosciences, Inc. 10-Q

Item 5. Other information. Not applicable. 102 Item 6. E xhibits . Exhibit Number Exhibit Description Incorporated by Reference Form Date Number Filed Herewith 3.1 Amended and Restated Certificate of Incorporation. 8-K 5/28/2019 3.1 3.2 Amended and Restated Bylaws. 8-K 5/28/2019 3.2 4.1 Reference is made to Exhibits 3.1 through 3.2 . 4.2 Form of Common Stock Certificate. S-1/A 5/13/2019 4.2 10.1† Amendment No. 2 to Clinical Trial Collaboration and Supply Agreement between Pfizer Inc. and IDEAYA Biosciences, Inc. dated as of April 8, 2021. X 31.1 Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 31.2 Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 32.1* Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 101.INS XBRL Instance Document X 101.SCH XBRL Taxonomy Extension Schema Document X 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document X 101.DEF XBRL Taxonomy Extension Definition Linkbase Document X 101.LAB XBRL Taxonomy Extension Labels Linkbase Document X 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document X † Certain information in this exhibit has been excluded pursuant to Regulation S-K, Item 601(b)(10). * The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of IDEAYA Biosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing. 103 SIGNA TURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereto duly authorized. IDEAYA Biosciences, Inc. Date: May 10, 2021 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer (Principal Executive Officer) Date: May 10, 2021 By: /s/ Paul Stone, J.D. Paul Stone, J.D. Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) 104